Q2 2026 13F · SEC CIK 1964437
Saturn V Capital Management LP
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $697.5M
- Reported positions
- 23
- Top holdings a year, 3 yrs
- +47.1%
- Assets under management
- $793.2M
Saturn V Capital Management LP is a hedge fund that reported 23 positions worth $697.5M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Amylyx Pharmaceuticals Inc (AMLX, 11.9%), Alumis Ord (ALMS, 11.8%), Abivax SA (ABVX, 9.9%). A portfolio copying its top holdings returned 47.1% a year over the last 3 years, against 20.4% for the S&P 500.
Saturn V Capital Management LP holdings all 23 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc | 11.9% | +6.3% | $83.0M |
| ALMSAlumis Ord | 11.8% | -9.0% | $82.0M |
| ABVXAbivax SA | 9.9% | -4.4% | $69.1M |
| PCVXVaxcyte Inc | 7.1% | +3.4% | $49.6M |
| IMMXImmix Biopharma Inc | 6.9% | +26.1% | $48.0M |
| PHVSPharvaris N V | 6.5% | +9.4% | $45.4M |
| JAZZJazz Pharmaceuticals PLC | 5.6% | -1.2% | $38.8M |
| CELCCelcuity Inc | 5.6% | +31.4% | $38.7M |
| IRONDisc Medicine Inc | 5.5% | +16.6% | $38.4M |
| CADLCandel Therapeutics Inc | 4.9% | +14.1% | $34.0M |
| XFORX4 Pharmaceuticals Inc | 4.7% | +8.0% | $32.6M |
| MNPRMonopar Therapeutics Inc | 4.1% | -9.7% | $28.9M |
| DYNDyne Therapeutics Inc | 3.4% | +9.4% | $23.5M |
| TRVITrevi Therapeutics Inc | 2.8% | — | $19.6M |
| ZURAZura Bio Ltd | 1.8% | +184.0% | $12.4M |
| SGMTSagimet Biosciences Inc | 1.6% | — | $11.4M |
| OCSOculis Holding AG | 1.4% | +32.5% | $9.5M |
| IKTInhibikase Therapeutics Inc | 1.1% | +0.1% | $7.9M |
| VIRVir Biotechnology Inc | 1.1% | — | $7.9M |
| IVVDInvivyd Inc | 1.1% | -23.4% | $7.3M |
| ANROAlto Neuroscience Inc | 0.7% | +105.4% | $4.8M |
| MSLESatellos Bioscience Inc | 0.4% | +0.0% | $2.7M |
| OVIDOvid Therapeutics Inc | 0.3% | -84.1% | $1.8M |
What Saturn V Capital Management LP bought and sold in Q2 2026, against Q1 2026.
New positions
- TRVI Trevi Therapeutics Inc2.8% of 13F
- SGMT Sagimet Biosciences Inc1.6% of 13F
- VIR Vir Biotechnology Inc1.1% of 13F
Added to
- ZURA Zura Bio Ltd+184.0% shares
- ANRO Alto Neuroscience Inc+105.4% shares
- OCS Oculis Holding AG+32.5% shares
- CELC Celcuity Inc+31.4% shares
- IMMX Immix Biopharma Inc+26.1% shares
- IRON Disc Medicine Inc+16.6% shares
- CADL Candel Therapeutics Inc+14.1% shares
- DYN Dyne Therapeutics Inc+9.4% shares
Reduced
- OVID Ovid Therapeutics Inc-84.1% shares
- IVVD Invivyd Inc-23.4% shares
- MNPR Monopar Therapeutics Inc-9.7% shares
- ALMS Alumis Ord-9.0% shares
Sold out
- COGT Cogent Biosciences Incwas 4.4%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +87.8% /yr
- S&P 500 +20.1%
- 3 years
- +47.1% /yr
- S&P 500 +20.4%
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $697.5M | 23 |
| Q1 2026 | $552.2M | 21 |
| Q4 2025 | $544.9M | 20 |
| Q3 2025 | $456.0M | 17 |
| Q2 2025 | $246.8M | 24 |
| Q1 2025 | $198.2M | 21 |
| Q4 2024 | $255.4M | 24 |
| Q3 2024 | $279.8M | 25 |
| Q2 2024 | $264.6M | 26 |
| Q1 2024 | $249.4M | 21 |
| Q4 2023 | $261.2M | 23 |
| Q3 2023 | $238.9M | 20 |
Questions about Saturn V Capital Management LP's portfolio
What stocks does Saturn V Capital Management LP own?
Saturn V Capital Management LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 23 positions worth $697.5M. The largest are Amylyx Pharmaceuticals Inc (AMLX) at 11.9%, Alumis Ord (ALMS) at 11.8%, Abivax SA (ABVX) at 9.9%, Vaxcyte Inc (PCVX) at 7.1% and Immix Biopharma Inc (IMMX) at 6.9%.
What did Saturn V Capital Management LP buy last quarter?
In Q2 2026, Saturn V Capital Management LP added a new position in Trevi Therapeutics Inc (TRVI), a new position in Sagimet Biosciences Inc (SGMT), a new position in Vir Biotechnology Inc (VIR), Zura Bio Ltd (ZURA) (+184.0% shares), Alto Neuroscience Inc (ANRO) (+105.4% shares) and Oculis Holding AG (OCS) (+32.5% shares), compared with its Q1 2026 filing.
What did Saturn V Capital Management LP sell last quarter?
In Q2 2026, Saturn V Capital Management LP sold all of Cogent Biosciences Inc (COGT), Ovid Therapeutics Inc (OVID) (-84.1% shares), Invivyd Inc (IVVD) (-23.4% shares) and Monopar Therapeutics Inc (MNPR) (-9.7% shares), compared with its Q1 2026 filing.
How has Saturn V Capital Management LP's portfolio performed?
A portfolio copying Saturn V Capital Management LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +47.1% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +87.8% against +20.1%.
When is Saturn V Capital Management LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. Saturn V Capital Management LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Saturn V Capital Management LP manage?
Saturn V Capital Management LP reported $793.2M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $697.5M.